In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

If so, would you combine them vs monotherapy? Patient ECOG is 1

Answer from: Medical Oncologist at Community Practice

This is a challenging situation and one I have encountered in clinic. The data for PARP inhibitors in NSCLC is limited. There have been limited trials for this specific population including NSCLC so I have extrapolated from the breast/ovarian experience. For instance, there was a phase II...

Comments

Medical Oncologist at Siri Onclogy and hematology Infusion Service
This patient should be on a clinical trial. In ref...

Please select the option that best describes you:

In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

Related Questions